Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.
As Healio previously reported, the FDA approved teprotumumab-trbw (Tepezza, Horizon Therapeutics) in January 2020 for the treatment of thyroid eye disease after trials found the agent reduced proptosis for adults who were recently diagnosed with thyroid eye disease and those with a high clinical activity score. New data from a phase 4 trial found